Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.
2.

Clinical Outcomes of the HIV Protease Inhibitor Nelfinavir With Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-Small Cell Lung Cancer: A Phase 1/2 Trial.

Rengan R, Mick R, Pryma DA, Lin LL, Christodouleas J, Plastaras JP, Simone CB 2nd, Gupta AK, Evans TL, Stevenson JP, Langer CJ, Kucharczuk J, Friedberg J, Lam S, Patsch D, Hahn SM, Maity A.

JAMA Oncol. 2019 Aug 22. doi: 10.1001/jamaoncol.2019.2095. [Epub ahead of print]

PMID:
31436839
3.

Comparison of regional lung perfusion response on longitudinal MAA SPECT/CT in lung cancer patients treated with and without functional tissue-avoidance radiation therapy.

Thomas HMT, Zeng J, Lee HJ Jr, Sasidharan BK, Kinahan PE, Miyaoka RS, Vesselle HJ, Rengan R, Bowen SR.

Br J Radiol. 2019 Aug 12:20190174. doi: 10.1259/bjr.20190174. [Epub ahead of print]

PMID:
31364397
4.

Voxel Forecast for Precision Oncology: Predicting Spatially Variant and Multiscale Cancer Therapy Response on Longitudinal Quantitative Molecular Imaging.

Bowen SR, Hippe DS, Chaovalitwongse WA, Duan C, Thammasorn P, Liu X, Miyaoka RS, Vesselle HJ, Kinahan PE, Rengan R, Zeng J.

Clin Cancer Res. 2019 Aug 15;25(16):5027-5037. doi: 10.1158/1078-0432.CCR-18-3908. Epub 2019 May 29.

PMID:
31142507
5.

Lessons Learned From Hurricane Maria in Puerto Rico: Practical Measures to Mitigate the Impact of a Catastrophic Natural Disaster on Radiation Oncology Patients.

Gay HA, Santiago R, Gil B, Remedios C, Montes PJ, López-Araujo J, Chévere CM, Imbert WS, White J, Arthur DW, Horton JK, Jagsi R, Rabinovich R, Beriwal S, Viswanathan A, Erickson BA, Rengan R, Palma D, Loo BW Jr, Kavanaugh JA, Bradley J, Yom SS, Harari PM, Lee Burnett O 3rd.

Pract Radiat Oncol. 2019 Sep - Oct;9(5):305-321. doi: 10.1016/j.prro.2019.03.007. Epub 2019 Apr 15.

6.

Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies.

Badiyan SN, Rutenberg MS, Hoppe BS, Mohindra P, Larson G, Hartsell WF, Tsai H, Zeng J, Rengan R, Glass E, Katz S, Vargas C, Feigenberg SJ, Simone CB 2nd.

Pract Radiat Oncol. 2019 Jul - Aug;9(4):280-288. doi: 10.1016/j.prro.2019.02.008. Epub 2019 Feb 23.

PMID:
30802618
7.

Empiric Radiotherapy for Lung Cancer Collaborative Group multi-institutional evidence-based guidelines for the use of empiric stereotactic body radiation therapy for non-small cell lung cancer without pathologic confirmation.

Berman AT, Jabbour SK, Vachani A, Robinson C, Choi JI, Mohindra P, Rengan R, Bradley J, Simone CB 2nd.

Transl Lung Cancer Res. 2019 Feb;8(1):5-14. doi: 10.21037/tlcr.2018.12.12. Review.

8.

Corneal Substructure Dosimetry Predicts Corneal Toxicity in Patients With Uveal Melanoma Treated With Proton Beam Therapy.

Lee HJ Jr, Stacey A, Klesert TR, Wells C, Skalet AH, Bloch C, Fung A, Bowen SR, Wong TP, Shibata D, Halasz LM, Rengan R.

Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):374-382. doi: 10.1016/j.ijrobp.2019.02.005. Epub 2019 Feb 11.

PMID:
30763658
9.

Analysis of Gastrointestinal Toxicity in Patients Receiving Proton Beam Therapy for Prostate Cancer: A Single-Institution Experience.

Lee HJ Jr, Macomber MW, Spraker MB, Bowen SR, Hippe D, Fung A, Russell KJ, Laramore GE, Rengan R, Liao J, Apisarnthanarax S, Zeng J.

Adv Radiat Oncol. 2018 Aug 13;4(1):70-78. doi: 10.1016/j.adro.2018.08.002. eCollection 2019 Jan-Mar.

10.

Direct synthesis of 2,4,5-trisubstituted imidazoles from primary alcohols by diruthenium(ii) catalysts under aerobic conditions.

Sundar S, Rengan R.

Org Biomol Chem. 2019 Feb 6;17(6):1402-1409. doi: 10.1039/c8ob02785d.

PMID:
30663756
11.

Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location.

Schonewolf CA, Heskel M, Doucette A, Singhal S, Frick MA, Xanthopoulos EP, Corradetti MN, Friedberg JS, Pechet TT, Christodouleas JP, Levin W, Berman A, Cengel KA, Verma V, Hahn SM, Kucharczuk JC, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2019 Jan;20(1):e63-e71. doi: 10.1016/j.cllc.2018.09.004. Epub 2018 Sep 20.

PMID:
30337269
12.

Early toxicity and patient reported quality-of-life in patients receiving proton therapy for localized prostate cancer: a single institutional review of prospectively recorded outcomes.

Lee HJ Jr, Macomber MW, Spraker MB, Bowen SR, Hippe DS, Fung A, Russell KJ, Laramore GE, Rengan R, Liao J, Apisarnthanarax S, Zeng J.

Radiat Oncol. 2018 Sep 17;13(1):179. doi: 10.1186/s13014-018-1127-6.

13.

Correlation of Functional Lung Heterogeneity and Dosimetry to Radiation Pneumonitis using Perfusion SPECT/CT and FDG PET/CT Imaging.

Lee HJ Jr, Zeng J, Vesselle HJ, Patel SA, Rengan R, Bowen SR.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1255-1264. doi: 10.1016/j.ijrobp.2018.05.051. Epub 2018 Jun 1.

PMID:
30108002
14.

The Practicality of ICRU and Considerations for Future ICRU Definitions.

Shepherd A, James SS, Rengan R.

Semin Radiat Oncol. 2018 Jun;28(3):201-206. doi: 10.1016/j.semradonc.2018.02.005. Review.

15.

Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer.

Lee HJ Jr, Zeng J, Rengan R.

Transl Lung Cancer Res. 2018 Apr;7(2):180-188. doi: 10.21037/tlcr.2018.03.28. Review.

16.

Decision analytic modeling for the economic analysis of proton radiotherapy for non-small cell lung cancer.

Smith WP, Richard PJ, Zeng J, Apisarnthanarax S, Rengan R, Phillips MH.

Transl Lung Cancer Res. 2018 Apr;7(2):122-133. doi: 10.21037/tlcr.2018.03.27.

17.

Advanced proton beam dosimetry part II: Monte Carlo vs. pencil beam-based planning for lung cancer.

Maes D, Saini J, Zeng J, Rengan R, Wong T, Bowen SR.

Transl Lung Cancer Res. 2018 Apr;7(2):114-121. doi: 10.21037/tlcr.2018.04.04.

18.

Proton therapy in non-small cell lung cancer.

Rengan R, Zeng J.

Transl Lung Cancer Res. 2018 Apr;7(2):103-105. doi: 10.21037/tlcr.2018.04.13. No abstract available.

19.

Challenge of Proving the Value of Proton Therapy in an Unselected Patient Population in the Era of Precision Oncology: The Fallacy of a One-Size-Fits-All Strategy in Radiotherapy for Lung Cancer.

Rengan R, Redman M, Zeng J.

J Clin Oncol. 2018 Jul 1;36(19):2003-2004. doi: 10.1200/JCO.2018.78.3803. Epub 2018 May 10. No abstract available.

PMID:
29746228
20.

4D computed tomography scans for conformal thoracic treatment planning: is a single scan sufficient to capture thoracic tumor motion?

Tseng YD, Wootton L, Nyflot M, Apisarnthanarax S, Rengan R, Bloch C, Sandison G, St James S.

Phys Med Biol. 2018 Jan 18;63(2):02NT03. doi: 10.1088/1361-6560/aaa44e.

PMID:
29346116
21.
22.

The Role of Advanced Imaging in Assessing Response to Definitive Chemoradiation Before Prophylactic Cranial Irradiation in Limited-Stage Small-Cell Lung Cancer.

Kesarwala AH, Lu DJ, Xanthopoulos E, Apisarnthanarax S, Cengel KA, Evans TL, Aggarwal C, Cohen RB, Langer CJ, Rengan R, Simone CB 2nd.

Clin Lung Cancer. 2018 Mar;19(2):e205-e209. doi: 10.1016/j.cllc.2017.10.001. Epub 2017 Oct 12.

23.

The relationship between cardiac radiation dose and mediastinal lymph node involvement in stage III non-small cell lung cancer patients.

McNew LK, Bowen SR, Gopan O, Nyflot MJ, Patel SA, Zeng J, Rengan R.

Adv Radiat Oncol. 2017 Feb 1;2(2):192-196. doi: 10.1016/j.adro.2017.01.008. eCollection 2017 Apr-Jun.

24.

Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.

Rwigema JM, Verma V, Lin L, Berman AT, Levin WP, Evans TL, Aggarwal C, Rengan R, Langer C, Cohen RB, Simone CB 2nd.

Cancer. 2017 Nov 1;123(21):4244-4251. doi: 10.1002/cncr.30870. Epub 2017 Jul 5.

25.

Dose Escalation Optimization in Patients With Locally Advanced Non-Small-Cell Lung Cancer: The Right Dose, in the Right Location, to the Right Patient, at the Right Time.

Zeng J, Rengan R.

JAMA Oncol. 2017 Oct 1;3(10):1365-1367. doi: 10.1001/jamaoncol.2017.1344. No abstract available.

PMID:
28570727
26.

Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma.

Kalbasi A, Rengan R.

Transl Lung Cancer Res. 2017 Apr;6(2):169-177. doi: 10.21037/tlcr.2017.03.03. Review.

27.

Functional lung avoidance and response-adaptive escalation (FLARE) RT: Multimodality plan dosimetry of a precision radiation oncology strategy.

Lee E, Zeng J, Miyaoka RS, Saini J, Kinahan PE, Sandison GA, Wong T, Vesselle HJ, Rengan R, Bowen SR.

Med Phys. 2017 Jul;44(7):3418-3429. doi: 10.1002/mp.12308. Epub 2017 Jun 1.

28.

Framework for radiation pneumonitis risk stratification based on anatomic and perfused lung dosimetry.

Dhami G, Zeng J, Vesselle HJ, Kinahan PE, Miyaoka RS, Patel SA, Rengan R, Bowen SR.

Strahlenther Onkol. 2017 May;193(5):410-418. doi: 10.1007/s00066-017-1114-0. Epub 2017 Mar 2.

29.

Oligometastatic non-small-cell lung cancer: current treatment strategies.

Richard PJ, Rengan R.

Lung Cancer (Auckl). 2016 Nov 4;7:129-140. doi: 10.2147/LCTT.S101639. eCollection 2016. Review.

30.

First Clinical Report of Proton Beam Therapy for Postoperative Radiotherapy for Non-Small-Cell Lung Cancer.

Remick JS, Schonewolf C, Gabriel P, Doucette A, Levin WP, Kucharczuk JC, Singhal S, Pechet TTV, Rengan R, Simone CB 2nd, Berman AT.

Clin Lung Cancer. 2017 Jul;18(4):364-371. doi: 10.1016/j.cllc.2016.12.009. Epub 2017 Jan 5.

PMID:
28162946
31.

An image-guided precision proton radiation platform for preclinical in vivo research.

Ford E, Emery R, Huff D, Narayanan M, Schwartz J, Cao N, Meyer J, Rengan R, Zeng J, Sandison G, Laramore G, Mayr N.

Phys Med Biol. 2017 Jan 7;62(1):43-58. Epub 2016 Dec 14.

PMID:
27973343
32.

Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer.

Chao HH, Berman AT, Simone CB 2nd, Ciunci C, Gabriel P, Lin H, Both S, Langer C, Lelionis K, Rengan R, Hahn SM, Prabhu K, Fagundes M, Hartsell W, Mick R, Plastaras JP.

J Thorac Oncol. 2017 Feb;12(2):281-292. doi: 10.1016/j.jtho.2016.10.018. Epub 2016 Nov 5.

33.

Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.

Maquilan G, Grover S, Xanthopoulos E, Evans TL, Aggarwal C, Langer CJ, Cohen RB, Stevenson JP, Simone CB 2nd, Rengan R.

Am J Clin Oncol. 2018 Apr;41(4):391-395. doi: 10.1097/COC.0000000000000288.

PMID:
27100960
34.

Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.

Chang JY, Jabbour SK, De Ruysscher D, Schild SE, Simone CB 2nd, Rengan R, Feigenberg S, Khan AJ, Choi NC, Bradley JD, Zhu XR, Lomax AJ, Hoppe BS; International Particle Therapy Co-operative Group Thoracic Subcommittee.

Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):505-16. doi: 10.1016/j.ijrobp.2016.01.036. Epub 2016 Jan 23. Review.

PMID:
27084663
35.

Factors Associated With Early Mortality in Patients Treated With Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.

Warner A, Dahele M, Hu B, Palma DA, Senan S, Oberije C, Tsujino K, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, De Ruyck K, De Dios NR, Bradley JD, Rodrigues G.

Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):612-20. doi: 10.1016/j.ijrobp.2015.11.030. Epub 2015 Nov 23. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):1087.

PMID:
26867890
36.

Education and Training Needs in Radiation Oncology in India: Opportunities for Indo-US Collaborations.

Grover S, Chadha M, Rengan R, Williams TR, Morris ZS, Morgan DA, Tripuraneni P, Hu K, Viswanathan AN.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):957-60. doi: 10.1016/j.ijrobp.2015.08.009. Epub 2015 Aug 7.

PMID:
26581132
37.

Ill-posed problem and regularization in reconstruction of radiobiological parameters from serial tumor imaging data.

Chvetsov AV, Sandison GA, Schwartz JL, Rengan R.

Phys Med Biol. 2015 Nov 7;60(21):8491-503. doi: 10.1088/0031-9155/60/21/8491. Epub 2015 Oct 20.

PMID:
26485348
38.

Proton Beam Therapy for Non-Small Cell Lung Cancer: Current Clinical Evidence and Future Directions.

Berman AT, James SS, Rengan R.

Cancers (Basel). 2015 Jul 2;7(3):1178-90. doi: 10.3390/cancers7030831. Review.

39.

Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis.

Rodrigues G, Oberije C, Senan S, Tsujino K, Wiersma T, Moreno-Jimenez M, Kim TH, Marks LB, Rengan R, De Petris L, Ramella S, DeRuyck K, De Dios NR, Warner A, Bradley JD, Palma DA.

Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):133-9. doi: 10.1016/j.ijrobp.2014.09.033. Erratum in: Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1115.

PMID:
25835622
40.

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.

Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ.

Nature. 2015 Apr 16;520(7547):373-7. doi: 10.1038/nature14292. Epub 2015 Mar 9.

41.

Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study.

Xanthopoulos EP, Handorf E, Simone CB 2nd, Grover S, Fernandes AT, Sharma S, Corradetti MN, Evans TL, Langer CJ, Mitra N, Shah A, Apisarnthanarax S, Lin LL, Rengan R.

Pract Radiat Oncol. 2015 Jul-Aug;5(4):e355-63. doi: 10.1016/j.prro.2014.11.006. Epub 2015 Jan 31.

PMID:
25649540
42.

Intensity-modulated proton therapy for elective nodal irradiation and involved-field radiation in the definitive treatment of locally advanced non-small-cell lung cancer: a dosimetric study.

Kesarwala AH, Ko CJ, Ning H, Xanthopoulos E, Haglund KE, O'Meara WP, Simone CB 2nd, Rengan R.

Clin Lung Cancer. 2015 May;16(3):237-44. doi: 10.1016/j.cllc.2014.12.001. Epub 2014 Dec 9.

43.

Stereotactic body radiotherapy.

Kollar L, Rengan R.

Semin Oncol. 2014 Dec;41(6):776-89. doi: 10.1053/j.seminoncol.2014.09.022. Epub 2014 Oct 7. Review.

PMID:
25499636
44.

The use of proton therapy in the treatment of lung cancers.

Simone CB 2nd, Rengan R.

Cancer J. 2014 Nov-Dec;20(6):427-32. doi: 10.1097/PPO.0000000000000080. Review.

PMID:
25415690
45.

Dynamic simulation of motion effects in IMAT lung SBRT.

Zou W, Yin L, Shen J, Corradetti MN, Kirk M, Munbodh R, Fang P, Jabbour SK, Simone CB 2nd, Yue NJ, Rengan R, Teo BK.

Radiat Oncol. 2014 Nov 1;9:225. doi: 10.1186/s13014-014-0225-3.

46.

Combination of stereotactic ablative body radiation with targeted therapies.

Zeng J, Baik C, Bhatia S, Mayr N, Rengan R.

Lancet Oncol. 2014 Sep;15(10):e426-34. doi: 10.1016/S1470-2045(14)70026-9. Review.

PMID:
25186046
47.

Phase I randomized double-blind placebo-controlled single-dose safety studies of Bowman-Birk inhibitor concentrate.

Lin LL, Mick R, Ware J, Metz J, Lustig R, Vapiwala N, Rengan R, Kennedy AR.

Oncol Lett. 2014 Apr;7(4):1151-1158. Epub 2014 Feb 5.

48.

International outreach: what is the responsibility of ASTRO and the major international radiation oncology societies?

Mayr NA, Hu KS, Liao Z, Viswanathan AN, Wall TJ, Amendola BE, Calaguas MJ, Palta JR, Yue NJ, Rengan R, Williams TR.

Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):481-4. doi: 10.1016/j.ijrobp.2013.12.052.

PMID:
24929158
49.

Impact of sociodemographic factors on the radiotherapeutic management of lung cancer: Results of a Quality Research in Radiation Oncology survey.

Rengan R, Ho A, Owen JB, Komaki R, Khalid N, Wilson JF, Movsas B.

Pract Radiat Oncol. 2014 May-Jun;4(3):e167-e179. doi: 10.1016/j.prro.2013.07.012. Epub 2013 Oct 8.

PMID:
24766691
50.

A moving target: Image guidance for stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Corradetti MN, Mitra N, Bonner Millar LP, Byun J, Wan F, Apisarnthanarax S, Christodouleas J, Anderson N, Simone CB 2nd, Teo BK, Rengan R.

Pract Radiat Oncol. 2013 Oct-Dec;3(4):307-15. doi: 10.1016/j.prro.2012.10.005. Epub 2012 Nov 29.

PMID:
24674403

Supplemental Content

Loading ...
Support Center